How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nadroparin-calcium-warfarin-sequential-anticoagulation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

nadroparin calcium-warfarin sequential anticoagulation — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nadroparin calcium-warfarin sequential anticoagulation (nadroparin calcium-warfarin sequential anticoagulation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant combination (LMWH + vitamin K antagonist). Area: Cardiovascular.

marketed Anticoagulant combination (LMWH + vitamin K antagonist) Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

nadroparin calcium-warfarin sequential anticoagulation (nadroparin calcium-warfarin sequential anticoagulation) — Qilu Hospital of Shandong University. A sequential anticoagulation regimen combining nadroparin calcium (low-molecular-weight heparin) followed by warfarin to prevent thromboembolism.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nadroparin calcium-warfarin sequential anticoagulation TARGET	nadroparin calcium-warfarin sequential anticoagulation	Qilu Hospital of Shandong University	marketed	Anticoagulant combination (LMWH + vitamin K antagonist)	Factor Xa, thrombin (nadroparin); vitamin K-dependent clotting factors II, VII, IX, X (warfarin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant combination (LMWH + vitamin K antagonist) class)

Qilu Hospital of Shandong University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nadroparin calcium-warfarin sequential anticoagulation — Competitive Intelligence Brief. https://druglandscape.com/ci/nadroparin-calcium-warfarin-sequential-anticoagulation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab